| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Lysyl oxidase homolog 3, 143-, Lysyl oxidase-like protein 3, LOXL3, LOXL |
| Entrez GeneID | 84695 |
| WB Predicted band size | 83.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This LOXL3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 715-744 amino acids from the C-terminal region of human LOXL3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条关于LOXL3抗体的模拟参考文献(基于公开研究领域常见主题，建议通过学术数据库核实具体文献)：
---
1. **标题**: *LOXL3-Specific Antibody Development and Its Application in Detecting Tumor Microenvironment Remodeling*
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种高特异性LOXL3抗体，验证了其在免疫组化和Western blot中的有效性，并发现LOXL3在乳腺癌微环境中通过调控胶原交联促进转移。
2. **标题**: *The Role of LOXL3 in Fibrosis: Insights from Antibody-Based Inhibition Studies*
**作者**: Chen L, et al.
**摘要**: 利用新型LOXL3抗体阻断其酶活性，发现LOXL3在肝纤维化中通过TGF-β通路促进肌成纤维细胞活化，提示其作为治疗靶点的潜力。
3. **标题**: *LOXL3 Antibody Characterization and Epigenetic Regulation in Melanoma*
**作者**: Rossi M, et al.
**摘要**: 通过LOXL3抗体的染色分析，揭示了黑色素瘤中LOXL3表达与组蛋白修饰异常的相关性，表明其可能参与表观遗传调控和耐药性形成。
4. **标题**: *Cross-Reactivity Evaluation of Commercial LOXL3 Antibodies: Implications for Research Accuracy*
**作者**: Kim J, et al.
**摘要**: 系统性评估了市售LOXL3抗体的特异性，发现部分抗体存在与非靶蛋白(如LOXL2)的交叉反应，强调抗体验证在肿瘤研究中的重要性。
---
如需具体文献，建议通过PubMed、Google Scholar等平台检索关键词“LOXL3 antibody”、“LOXL3 function”或结合疾病名称(如“cancer”、“fibrosis”)。
**Background of LOXL3 Antibody**
Lysyl oxidase-like 3 (LOXL3) is a member of the lysyl oxidase (LOX) family, which catalyzes the cross-linking of collagen and elastin in the extracellular matrix (ECM) by oxidizing lysine residues. LOXL3. encoded by the *LOXL3* gene, shares structural features with other LOX family members, including copper-binding sites and cytokine receptor-like domains. Unlike other isoforms, LOXL3 exhibits both intracellular and extracellular roles, influencing ECM remodeling, cell adhesion, and signaling pathways. It is implicated in diverse biological processes, including embryonic development, tissue repair, and cancer progression.
LOXL3 dysregulation has been linked to pathological conditions such as fibrosis, metastatic cancers (e.g., melanoma, breast cancer), and genetic disorders like autosomal dominant Stickler syndrome. Its involvement in epithelial-mesenchymal transition (EMT), angiogenesis, and resistance to chemotherapy highlights its therapeutic potential. However, LOXL3's functional mechanisms remain partially understood, partly due to overlapping roles with other LOX proteins.
LOXL3 antibodies are critical tools for studying its expression, localization, and interactions. Polyclonal and monoclonal antibodies targeting specific domains (e.g., scavenger receptor cysteine-rich or catalytic regions) enable applications in Western blotting, immunohistochemistry, and functional assays. Challenges include ensuring specificity, as LOXL3 shares epitopes with other LOX isoforms. Recent research focuses on developing high-affinity LOXL3 antibodies for diagnostic and therapeutic exploration, particularly in cancers and fibrotic diseases. Validated antibodies are essential for clarifying LOXL3’s role in disease and its potential as a biomarker or drug target.
×
